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Systemic	Therapies	Antimetabolites	 Methotrexate	 Inhibits	dihydrofolate	reductase	activity	which	disrupts	DNA	synthesis,	thereby	reducing	skin	cell	proliferation	Calcineurin	inhibitors	 Cyclosporine	 Down-regulates	T	cell	activity	





























































Table	2:	Patient	Characteristics	Parameters	 Psoriasis	with	depression,	N=36	 Psoriasis	without	depression,	N=36	 P		Demographics	and	clinical	history	Age	(years)	 48.7	±	12.4	 49.0	±	12.3	 matched	Males,	N	(%)	 18	(50%)	 18	(50%)	 matched	Body	Mass	Index	 30.0	±	6.6	 28.5	±	4.7	 0.13	Hypertension,	N	(%)	 13	(36%)	 7	(19%)	 0.11	Type	2	diabetes,	N	(%)	 3	(8%)	 3	(8%)	 1.00	Hyperlipidemia,	N	(%)	 17	(47%)	 17	(47%)	 1.00	Current	tobacco	use,	N	(%)	 7	(19%)	 7	(19%)	 0.17	Personal	history	of	CAD,	N	(%)	 2	(6%)	 3	(8%)	 0.64	Family	history	of	CAD,	N	(%)	 11	(31%)	 15	(42%)	 0.33	Exercise	frequency	≥	once	weekly,	N	(%)*	 29	(88%)	 29	(94%)	 0.44	Cardiovascular	risk	profile	Systolic	BP,	mmHg	 125.5	±	19.0	 120.2	±	14.7	 0.10	Diastolic	BP,	mmHg	 74.1	±	10.2	 71.3	±	10.3	 0.13	Total	cholesterol,	mmol/L	 4.79	±	1.03	 4.57	±	0.99	 0.18	LDL	cholesterol,	mmol/L	 2.75	±	0.84	 2.56	±	0.79	 0.17	HDL	cholesterol,	mmol/L	 1.35	±	0.42	 1.44	±	0.43	 0.17	Framingham	Risk	score	[median	(IQR)]	 4	(1-6)	 2.5	(1-5)	 0.56	Hs-CRP,	nmol/L	[median	(IQR)]	 20.95	(9.71-41.43)	 22.86	(6.67-62.86)	 0.84	Psoriasis	characteristics	Disease	duration,	years	 22.3	±	15.5	 20.5	±	15.3	 0.31	Body	surface	area	affected,	%	[median	(IQR)]	 4.5	(2.8-17.4)	 3.4	(1.7-13.2)	 0.34	PASI	score	[median	(IQR)]	 6.3	(3.2-13.7)	 4.7	(2.8-12.8)	 0.25	Systemic	or	biologic	therapy,	N	(%)	 12	(33%)	 14	(39%)	 0.62		 Continuous	variables	are	expressed	as	Mean	±	Standard	Deviation	unless	specified	otherwise.	Hs-CRP	.	High	sensitivity	C-reactive	protein,	PASI	.	Psoriasis	Area	and	Severity	Index.		*N	=	33	vs.	31.		
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Table	3:		Markers	of	Subclinical	Atherosclerosis.		(A)	Vascular	Inflammation	by	
Depression	Status.		(B)	Coronary	Plaque	Burden	by	Depression	Status	Parameter	 Comorbid	depression	 No	psychiatric	history	 P		A	Vascular	inflammation	by	FDG-PET/CT	Total	aortic	TBR	 1.82	±	0.34	 1.66	±	0.18	 0.008	
Aortic	arch	TBR	 1.98	±	0.36	 1.84	±	0.21	 0.02	
Descending	aortic	TBR	 1.81	±	0.37	 1.65	±	0.18	 0.01	
	Suprarenal	aortic	TBR	 1.90	±	0.42	 1.69	±	0.24	 0.007	
	Infrarenal	aortic	TBR	 1.79	±	0.40	 1.59	±	0.19	 0.003	
	B	Plaque	burden	adjusted	for	luminal	attenuation	Total	burden	(x	100),	mm2	[median	(IQR)]	 1.11	(0.85-1.49)	 0.98	(0.81-1.22)	 0.04	
	
Non-calcified	burden	(x	100),	mm2	[median	(IQR)]	 1.10	(0.83-1.45)	 0.93	(0.78-1.21)	 0.03	
	










	A	 No	systemic/biologic	(N=46)	 Systemic/biologic	(N=26)	Parameter	 Dep	(N=24)	 No	Dep	(N=22)	 p-value	 Dep	(N=12)	 No	Dep	(N=14)	 P	Aortic	TBR	 1.85	±	0.37	 1.61	±	0.14	 0.003	 1.75	±	0.28	 1.73	±	0.21	 0.42		Total	plaque	burden	 1.46	±	1.12	 1.05	±	0.35	 0.006	 1.11	±	0.32	 1.11	±	0.46	 0.49		Non-calcified	burden	 1.42	±	1.10	 1.02	±	0.36	 0.006	 1.09	±	0.31	 1.09	±	0.46	 0.49		Dep=	Self-reported	Depression.										
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Parameter	 Self-Reported	Psych	Diagnosis	N=41	 No	Self-Reported	Psych	Diagnosis	N=41	 P	Demographics	and	Clinical	Characteristics	Age,	years	 49.1±13.0	 49.3±12.9	 0.47	Males,	n	(%)	 20	(49)	 20	(49)	 1	Body	mass	index,	kg/m2	 30.0±6.4	 28.3±4.6	 0.08	Hypertension,	n	(%)	 14	(34)	 9	(22)	 0.22	Type-2	diabetes,	n	(%)	 4	(10)	 3	(7)	 0.69	Hyperlipidemia,	n	(%)	 20	(49)	 19	(46)	 0.83	Current	tobacco	use,	n	(%)	 7	(17)	 3	(7)	 0.18	Clinical	and	Lab	Parameters	Systolic	blood	pressure,	mm	Hg	 125.8±18.2	 120.4±14.8	 0.07	Diastolic	blood	pressure,	mm	Hg	 73.6±10.1	 72.0±10.5	 0.24	Total	Cholesterol,	mg/dL	 185.0±38.5	 179.4±38.2	 0.25	LDL	cholesterol,	mg/dL	 106.1±32.0	 97.1±32.7	 0.11	
HDL	cholesterol,	mg/dL	 50.6±16.0	 58.8±19.4	 0.02	
Triglycerides,	mg/dL	 115	(90-179)	 92	(76-119)	 0.02	Framingham	risk	score	 4	(1-6.5)	 2	(1-4)	 0.31	HOMA-IR	 3.4	(1.6-5.6)	 2.6	(1.7-3.6)	 0.28	Apolipoprotein	A,	mg/dL	 152.7±27.9	 159.9±34.3	 0.15	Apolipoprotein	B,	mg/dL	 92.9±19.0	 87.0±20.1	 0.09	Psoriasis	Characteristics	Disease	duration,	years	 22.2±14.7	 20.3±15.6	 0.29	PASI	score	 5.4	(3.1-12.3)	 5.1	(2.8-12.8)	 0.46	Amygdala	Target-to-Background	Ratio	
Left	Amygdala	TBR	 0.85±0.09	 0.81±0.09	 0.01	Values	are	reported	as	mean±S.D.	or	median	(IQR)	for	continuous	variables	and	as	N	(%)	for	categorical	variables.	P	values	are	calculated	by	student’s	t-test	or	Mann-Whitney	U-test	for	continuous	variables	depending	on	the	normality	and	by	Pearson’s	chi-square	test	for	categorical	variables.	HOMA-IR=Homeostatic	Model	Assessment	of	Insulin	Resistance,	PASI=Psoriasis	Area	Severity	Index,	TBR=Target-to-Background	Ratio.	
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Discussion	
Context	and	Significance	This	study	is	the	first	to	evaluate	the	association	between	self-reported	depression	and	vascular	inflammation	in	patients	with	the	chronic	inflammatory	disorder,	psoriasis.		We	show	that	psoriasis	patients	who	report	comorbid	depression	experience	significantly	increased	vascular	inflammation,	total	coronary	plaque	burden,	and	non-calcified	coronary	plaque	burden.		We	also	show	that	these	observed	increases	exist	after	adjustment	for	Framingham	risk,	suggesting	that	depression	itself	may	play	a	role	in	promoting	subclinical	atherosclerosis	beyond	what	is	attributable	to	traditional	cardiovascular	risk.	A	stratified	analysis	of	the	patient	cohort	revealed	that	the	relationship	seen	between	self-reported	depression	and	markers	of	subclinical	atherosclerosis	is	stronger	in	the	absence	of	systemic	or	biologic	treatment	and	diminished	by	the	use	of	these	anti-inflammatory	therapies.		These	findings	suggest	that	anti-inflammatory	therapy	may	modify	the	relationship	between	depression	and	cardiovascular	disease	in	psoriasis.		Overall,	the	results	of	this	study	support	the	notion	that	patients	with	psoriasis,	who	are	already	at	increased	cardiovascular	risk	due	to	chronic	inflammation,	incur	even	greater	risk	with	comorbid	depression	that	is	not	attributable	to	traditional	cardiovascular	risk	factors.		Careful	screening	for	psychiatric	comorbidities	and	provision	of	appropriate	mental	health	care	for	patients	with	psoriasis	may	be	warranted	for	further	prevention	of	atherosclerosis.			Over	the	years,	several	studies	have	pointed	at	depression	as	a	causal	factor	in	cardiovascular	disease.(39,40)		Depression	has	been	shown	to	correlate	with	
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myocardial	infarction,	stroke	and	sudden	death.(41,42)		Both	depression	and	anxiety	have	been	associated	with	atherosclerosis,	although	to	differing	degrees.		Therefore,	we	chose	to	include	patients	who	reported	suffering	from	both	depression	and	anxiety	concurrently,	in	addition	to	patients	reporting	depression	alone.		Nonetheless,	it	is	important	to	keep	in	mind	that	causal	mechanisms	are	complex	and	may	differ	between	the	two	mood	disorders	in	terms	of	their	impact	on	atherosclerosis.	As	cardiovascular	imaging	techniques	have	improved,	availability	of	accurate,	non-invasive	modalities	have	led	to	a	greater	focus	on	early	markers	of	cardiovascular	disease.		These	modalities	allow	us	to	better	understand	the	process	of	atherosclerosis	as	it	occurs,	before	the	onset	of	devastating	cardiovascular	events.		The	existing	literature	examining	psychological	stress	as	an	independent	driver	of	atherosclerosis	is	small,	but	growing.		The	data	we	do	have	seem	to	support	the	idea	that	psychological	stress	promotes	atherosclerosis	and	that	this	process	is	at	least	in	part	mediated	by	inflammation.		The	results	from	this	study	lend	further	support	to	the	existing	evidence	by	showing	that	subclinical	cardiovascular	disease	is	increased	in	psoriasis	patients	with	self-reported	depression	beyond	what	is	attributable	to	traditional	cardiovascular	risk.					In	a	subsequent	study	of	a	similar	patient	population	we	follow-up	our	previous	results	by	quantifying	psychological	stress	using	amygdala	uptake	of	FDG	on	FDG	PET/CT	scans	of	the	brain.		A	recent	study	of	293	healthy	patients	conducted	at	Massachusetts	General	Hospital	demonstrated	a	robust	relationship	between	amygdala	activity	and	cardiovascular	events,	bone	marrow	activity	and	arterial	inflammation.(43)		Our	follow-up	study	reinforces	and	expands	upon	the	findings	from	this	recent	study	
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conducted	in	a	low-risk	population	of	patients	without	coronary	artery	disease.		We	are	able	to	show	in	a	psoriasis	population	that	both	that	left	amygdala	FDG	uptake	target-to-background	ratio	is	increased	in	patients	who	report	a	history	of	depression	and/or	anxiety,	and	that	these	patients	experience	greater	vascular	inflammation	and	decreased	vascular	function.		Furthermore,	we	go	on	to	show	that	vascular	function	remains	significantly	associated	with	left	amygdala	uptake	after	adjustment	for	Framingham	risk,	suggesting	that	the	extent	of	vascular	dysfunction	cannot	be	fully	attributed	to	traditional	cardiovascular	risk.		These	findings	further	underscore	the	impact	of	psychological	stress	on	cardiovascular	disease.		In	this	study	we	are	able	to	observe	the	atherosclerotic	process	at	an	earlier	stage	in	the	natural	history,	but	where	vulnerable	patients	already	begin	to	diverge	from	their	counterparts	with	less	psychological	burden.						
Strengths	and	Limitations		 The	strengths	of	this	study	are	that	it	uses	a	deeply-phenotyped	cohort	of	patients,	validated	non-invasive	cardiovascular	imaging	modalities	are	used	to	examine	intermediate	outcomes,	and	that	psychological	stress	is	examined	in	two	different	ways:	self-reported	diagnosis	and	imaging	of	the	amygdala,	a	region	of	the	brain	involved	in	processing	stress.		Limitations	include	the	sample	size,	lack	of	longitudinal	data	for	follow-up	and	the	lack	of	standardized	metrics	for	quantifying	psychological	stress	such	as	depression	inventories.		In	the	future,	larger	studies	that	follow	patients	out	several	years	to	observe	the	progression	of	disease	burden	will	allow	for	a	better	
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understanding	of	the	impact	of	psychological	stress	on	atherosclerosis	in	patients	with	and	without	chronic	inflammation.							
Conclusion			 Overall,	in	this	study	we	demonstrate	that	psychological	stress	in	patients	with	the	chronic	inflammatory	disorder,	psoriasis,	associates	with	greater	subclinical	cardiovascular	disease	and	vascular	dysfunction.		Chronic	stress	may,	therefore,	play	a	key	role	in	the	development	and	progression	of	atherosclerosis	beyond	what	can	be	explained	by	links	to	detrimental	lifestyle	or	traditional	cardiovascular	risk.		As	this	is	a	small,	cross-sectional	study,	causation	cannot	be	determined	from	the	results	of	this	work,	however,	we	provide	the	basis	from	which	future	studies	may	further	evaluate	the	mechanistic	links	between	chronic	inflammation,	psychological	stress	and	cardiovascular	disease.		Furthermore,	we	identify	a	patient	population	that	is	at	even	greater	risk	of	cardiovascular	disease	through	comorbid	psychiatric	disease,	which	may	not	be	well-served	by	conventional	prognostication	methods	that	do	not	take	such	comorbidities	into	account.		Patients	who	suffer	from	psoriasis	and	other	chronic	inflammatory	diseases	may	benefit	from	better	risk	stratification	that	is	inclusive	of	psychological	stress	and	targeted	care	for	psychiatric	comorbidities	in	order	to	reduce	future	risk	of	adverse	cardiovascular	outcomes.					
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